Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,143
  • Shares Outstanding, K 45,037
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,180 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.41
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.02 on 08/11/22
  • Next Earnings Date 11/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.249 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0710 +29.58%
on 09/06/22
0.1320 -30.30%
on 09/20/22
+0.0128 (+16.16%)
since 09/02/22
3-Month
0.0616 +49.35%
on 08/25/22
0.1320 -30.30%
on 09/20/22
-0.0030 (-3.16%)
since 07/05/22
52-Week
0.0521 +76.58%
on 06/29/22
0.8600 -89.30%
on 11/09/21
-0.4578 (-83.27%)
since 10/05/21

Most Recent Stories

More News
LadRx Corporation Announces OTCQB Ticker Change to LADX

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing...

CYTR : 0.0920 (unch)
LADX : 1.8400 (+5.14%)
CytRx Corporation Relaunches as LadRx Corporation

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching...

CYTR : 0.0920 (unch)
European Patent Office Awards CytRx Key Patent

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded...

CYTR : 0.0920 (unch)
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne...

CYTR : 0.0920 (unch)
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board...

CYTR : 0.0920 (unch)
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic...

CYTR : 0.0920 (unch)
CytRx Partners with Oncology Development Expert to Advance LADR Platform

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered...

CYTR : 0.0920 (unch)
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to...

CYTR : 0.0920 (unch)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Key Turning Points

3rd Resistance Point 0.1080
2nd Resistance Point 0.1040
1st Resistance Point 0.0980
Last Price 0.0920
1st Support Level 0.0880
2nd Support Level 0.0840
3rd Support Level 0.0780

See More

52-Week High 0.8600
Fibonacci 61.8% 0.5514
Fibonacci 50% 0.4561
Fibonacci 38.2% 0.3607
Last Price 0.0920
52-Week Low 0.0521

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar